The pathologic complete response (pCR) after neoadjuvant chemotherapy is well known to be associated with a favorable prognosis, especially in patients with HER2-positive (HER2+) breast cancer and triple-negative breast cancer (TNBC) [6,7,8,9]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.